Is acer a good stock to invest for a couple of years into?

Acer Therapeutics Inc (ACER) does not appear to be a strong investment option in the short term, based on the following analysis:

1. Analyst Ratings and Price Target: The consensus rating for Acer Therapeutics is "Hold," with no buy ratings and two hold ratings given by analysts in the past three months. The average 12-month price target is $1.50, representing a significant upside from the last price of $0.66. This suggests that analysts do not see a strong immediate growth trajectory.

2. Stock Performance Forecast: The stock price forecasts for the next few months show volatility with a high degree of uncertainty. The price is expected to fluctuate, with predictions ranging from $0.47 to $1.95 over the next 14 days. Long-term forecasts are not more promising, with predictions indicating a potential decrease in price by November 2024 and a slight increase by January 2025.

3. Company Financial Health: Acer's financial health is not robust, as indicated by its low current stock price and the need for significant price appreciation to meet analyst price targets. The company's recent financial performance and market position do not support a strong investment case at this time.

4. Market Conditions: The PC market, where Acer operates, has faced challenges, with a 15% decline in shipments in 2023 due to inventory rebalancing and an unfavorable economic climate. While there are signs of recovery, the market remains competitive, with Lenovo and HP holding a significant market share.

In conclusion, while Acer has made efforts to innovate and adapt to the AI and sustainability trends, the current analyst sentiment and stock performance forecasts do not support a positive outlook for ACER stock in the short term. Investors should exercise caution and consider the high degree of uncertainty before investing in ACER stock.